Wesley Tanaka - Concepedia

Author

Wesley Tanaka

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

L. Kristensen, W K Tanaka, W TANAKA, W Tanaka, W. K. Tanaka, W. Tanaka, W.K. Tanaka, Wajeeha Razaq Takemi Tanaka, Waka Tanaka, Wataru Tanaka

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy MSD (Belgium)KU Leuven Clinical Research Associates

About

Wesley Tanaka is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and chromatography.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	1.1K
2	Natural Sciences	2	2	38
3	Engineering	1	1	15
4	Health Sciences	1	1	17
5	Allergy	1	1	161

Wesley Tanaka

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Plasma MicroRNAs as Sensitive and Specific Biomarkers of Tissue Injury Omar Laterza, Lee P. Lim, Philip W. Garrett-Engele, Clinical Chemistry	2009	613
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses Gary Herman, C. Melinda Stevens, Koen Vandyck, Clinical Pharmacology & Therapeutics	2005	514
Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes Gary Herman, Arthur Bergman, Catherine Stevens, The Journal of Clinical Endocrinology & Metabolism	2006	498
Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers Anne Van Hecken, Jules I. Schwartz, Marleen Depré, The Journal of Clinical Pharmacology	2000	355
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers Arthur Bergman, Catherine Stevens, Yanyan Zhou, Clinical Therapeutics Pharmacological StudyMedicineHealthy Male VolunteersPlacebo-controlled StudyPharmacotherapy	2006	265
Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist Theodore F. Reiss, J. B. Hill, Eloise Harman, Thorax	1997	208
The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. A. Dallob, Neil S. Sadick, Walter Unger, The Journal of Clinical Endocrinology & Metabolism AndrologyUrologyBald ScalpMedicineAlpha-reductase Inhibitor	1994	197
Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects Gary Herman, Arthur Bergman, Fang Liu, The Journal of Clinical Pharmacology Middle‐aged Obese SubjectsPharmacotherapyInsulin SignalingObesityMetabolic Syndrome	2006	184
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia Lynn A. Drake, Maria Hordinsky, Virginia C. Fiedler, Journal of the American Academy of Dermatology Serum Androgen LevelsMedicineScalp SkinSkin PharmacologyDermatology	1999	182
Oral Leukotriene Inhibitor (MK-886) Blocks Allergen-induced Airway Responses Beth S. Friedman, Elizabeth H. Bel, A. Buntinx, American Review of Respiratory Disease AsthmaInflammationEnvironmental AllergyAllergyInflammatory Lung Disease	1993	161

Page 1